U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. About FDA
  3. Performance Data
  4. FDA-TRACK: Agency-wide Program Performance
  5. FDA-TRACK: Center for Biologics Evaluation and Research - Goal 3
  1. FDA-TRACK: Agency-wide Program Performance

FDA-TRACK: Center for Biologics Evaluation and Research - Goal 3

FDA-TRACK: Biologics
FDA-TRACK Home Page

FDA's Center for Biologics Evaluation and Research (CBER) regulates biological products for human use under applicable federal laws, including the Public Health Service Act and the Federal Food, Drug and Cosmetic Act. CBER protects and advances the public health by ensuring that biological products are safe and effective and available to those who need them. CBER also provides the public with information to promote the safe and appropriate use of biological products.

During public health emergencies, the American public relies on CBER to proactively enhance response preparedness.  This means the discovery, development, production, and distribution of regulated products to counter these threats and resolve public health emergencies.  As many of the products FDA regulates directly address infectious disease threats that are not unique to the U.S., CBER carries out its regulatory responsibilities through international engagements that support both national and global health.

Goal 3: Increase Preparedness for Emerging Threats and Promote Global Public Health

Download Goal 3 Dataset

Note:  The data provided on this website is produced on an ongoing basis for performance management purposes and is subject to change due to updates of preliminary estimates, corrections, or other reasons.

Sign up to receive FDA-TRACK updates

Get regular FDA email updates delivered on this topic to your inbox.

Back to Top